Bonus episode
Join Isabel and Jade for this special episode of the GOLD podcast as three of last year’s guests share their predictions for the pharmaceutical industry in 2024.
The panel includes Matt Lewis from Inizio, Rick Hollis from Ipsen and Claudia Martinez from the Access to Medicine Foundation, all of whom share their predictions in their areas of expertise.
But that’s not all. The GOLD hosts also reminisce about the team’s 2023 predictions podcast to see if these guests could really see the future.
A little more on GOLD’s guests…
Matt Lewis is Co-Founder, Inizio Medical Analytics and Innovation. Based in New York, he leads a team dedicated to transforming innovation in the life sciences. Prior to Inizio, Matt worked at Procter & Gamble, Boehringer Ingelheim and a number of medical communications agencies, and his experience spans most major therapeutic areas. Matt also holds four degrees, including one in Molecular Biology from Cornell University and one in Population Health from New York University.
Rick Hollis is Director of Business Excellence at Ipsen, a role he has held for almost a year. Prior to joining Ipsen, Rick began his career in the pharmaceutical industry as a medical sales representative. He then went on to gain 20 years’ experience in pharma sales and marketing in the oncology, haematology and neuroscience fields. More recently, he has been turning his attention to how the customer experience can be fine-tuned.
Claudia Martínez is Head of research at the Access to Medicine Foundation. She is responsible for the strategic development, implementation and delivery of end-to-end research programmes at the Access to Medicine Foundation. Her role is to mobilise key players in the pharmaceutical industry to improve access to essential medicines in low- and middle-income countries. Since 2021, she has led the Foundation’s new research stream on access to generic medicines, overseeing and supporting the development of a first-of-its-kind analytical framework to assess how manufacturers can improve access to their products.
